Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.78 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2974293 | 1.00 | SIGMAR1 (0.78) | SIGMAR1LMNAPOLBALDH1A1MEN1 | |
| SCHEMBL65364 | 1.00 | SIGMAR1 (0.78) | SIGMAR1LMNAPOLBALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL21315849 | 0.98 | SIGMAR1 (0.76) | SIGMAR1LMNAPOLBALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL21315850 | 0.98 | SIGMAR1 (0.76) | SIGMAR1LMNAPOLBALDH1A1MEN1 | |
| SCHEMBL5639480 | 0.92 | SIGMAR1 (0.67) | SIGMAR1ALDH1A1 | |
| SCHEMBL3494735 | 0.88 | SIGMAR1 (0.80) | SIGMAR1LMNAPOLBALDH1A1MEN1 | |
| SCHEMBL4836976 | 0.88 | SIGMAR1 (0.80) | SIGMAR1LMNAPOLBALDH1A1MEN1 | |
| SCHEMBL2419294 | 0.86 | SIGMAR1 (0.60) | SIGMAR1LMNA | |
| SCHEMBL5710391 | 0.86 | SIGMAR1 (0.60) | SIGMAR1LMNAPOLBGAA | |
| SCHEMBL21315846 | 0.85 | SIGMAR1 (0.59) | SIGMAR1LMNAPOLBALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216361-A1 | ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B V (US) | 2024-07-04 | — | — | US | disclosed |
| US-20230277527-A1 | ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B.V. | 2023-09-07 | — | — | US | disclosed |
| CN-110139652-B | ROR-gamma modulators | 爱思凯利尔生物科学私人有限责任公司 | 2022-10-11 | — | — | CN | disclosed |
| EP-3532062-B1 | ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES BV (US) | 2022-07-20 | — | — | EP | disclosed |
| US-20220175765-A1 | ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B.V. | 2022-06-09 | — | — | US | disclosed |
| US-20210069182-A1 | ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B.V. | 2021-03-11 | — | — | US | disclosed |
| US-10905687-B2 | Substituted piperazines as ROR-gamma modulators | ESCALIER BIOSCIENCES B.V. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20190269674-A1 | ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES, BV (US) | 2019-09-05 | — | — | US | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-7625909-B2 | Substituted quinazolinone compounds | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625909-B2 | Substituted quinazolinone compounds | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20090054440-A1 | Quinoline derivatives as neurokinin receptor antagonists | CARLING WILLIAM ROBERT | 2009-02-26 | — | — | US | disclosed |
| US-7368453-B2 | Quinazolinone compounds with reduced bioaccumulation | CHIRON CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368453-B2 | Quinazolinone compounds with reduced bioaccumulation | CHIRON CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368453-B2 | Quinazolinone compounds with reduced bioaccumulation | CHIRON CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| EP-1651229-A1 | GUANIDINO-SUBSTITUTED QUINAZOLINONE COMPOUNDS AS MC4-R AGONISTS | Chiron Corporation (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050192297-A1 | Quinazolinone compounds with reduced bioaccumulation | CHIRON CORPORATION GLAXOSMITHKLINE | 2005-09-01 | — | — | US | disclosed |
| US-20050059662-A1 | Substituted quinazolinone compounds | CHIRON CORPORATION | 2005-03-17 | — | — | US | disclosed |
| WO-2004112793-A1 | GUANIDINO-SUBSTITUTED QUINAZOLINONE COMPOUNDS AS MC4-R AGONISTS | CHIRON CORPORATION (US) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059662-A1 | Substituted quinazolinone compounds | MC4R, MC2R, MC3R | SIGMAR1 1329/4885LMNA 3489/4885POLB 3304/4885 |
| US-20230277527-A1 | ROR-GAMMA MODULATORS | RORB, RORC, RORA | SIGMAR1 1215/4885LMNA 2990/4885POLB 2301/4885 |
| US-20240216361-A1 | ROR-GAMMA MODULATORS | RORB, RORC, RORA | SIGMAR1 1215/4885LMNA 2990/4885POLB 2301/4885 |
| US-20210069182-A1 | ROR-GAMMA MODULATORS | RORB, RORC, RORA | SIGMAR1 1215/4885LMNA 2990/4885POLB 2301/4885 |
| US-20090054440-A1 | Quinoline derivatives as neurokinin receptor antagonists | TACR2, TACR3, NPY2R | SIGMAR1 367/4885LMNA 2882/4885POLB 4645/4885 |
| US-10905687-B2 | Substituted piperazines as ROR-gamma modulators | RORC, RORA, RORB | SIGMAR1 477/4885LMNA 2539/4885POLB 1965/4885 |
| US-20220175765-A1 | ROR-GAMMA MODULATORS | RORB, RORC, RORA | SIGMAR1 1215/4885LMNA 2990/4885POLB 2301/4885 |
| US-20050192297-A1 | Quinazolinone compounds with reduced bioaccumulation | MC4R, MC2R, MC3R | SIGMAR1 348/4885LMNA 3436/4885POLB 2626/4885 |
| US-20190269674-A1 | ROR-GAMMA MODULATORS | RORB, RORC, RORA | SIGMAR1 1215/4885LMNA 2990/4885POLB 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.